Otsuka Pharmaceutical's experimental drug, sibeprenlimab, has shown promising results in a Phase 3 trial for IgA nephropathy, a rare kidney disease, demonstrating a significant reduction in protein levels in urine, a key indicator of kidney health. The company plans to discuss accelerated approval with the FDA while the trial continues, expected to conclude in early 2026. This development validates Otsuka's acquisition of Visterra, which focuses on immune diseases, and positions sibeprenlimab as a potential first-in-class treatment for IgAN.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
